AADI
vs
S&P 500
AADI
S&P 500
Over the past 12 months, AADI has underperformed S&P 500, delivering a return of -15% compared to the S&P 500's +13% growth.
Stocks Performance
AADI vs S&P 500
Performance Gap
AADI vs S&P 500
Performance By Year
AADI vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Aadi Bioscience Inc
Glance View
Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Pacific Palisades, California and currently employs 39 full-time employees. The company went IPO on 2018-06-26. The Company’s primary focus is to bring transformational therapies to cancer patients with mechanistic target of rapamycin (mTOR) pathway driver alterations such as alterations in TSC1 or TSC2 genes. The Company’s initial focus is the treatment of an ultra-rare cancer perivascular epithelioid cell tumor (PEComa). The Company’s lead product, FYARROTM, is an mTOR inhibitor bound to human albumin that has tumor accumulation, mTOR target suppression, and tumor growth inhibition over other mTOR inhibitors in preclinical models. FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with advanced unresectable or metastatic perivascular epithelioid cell tumor (PEComa).